Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi and Regeneron's Dupixent (dupilumab) wins Japan approval for bullous pemphigoid following Ph2/3 success
Antibody, autoimmune, monoclonal antibody, bullous pemphigoid, IL-4 receptor antagonist, dupilumab - Read more

Merck & Co., Quotient Therapeutics partner on IBD drug discovery, $20M upfront, $2.2B milestones
Research collaboration, autoimmune, drug discovery, milestone payments - Read more

Icon, Advarra partner to launch connected clinical trial site network using AI platform
Research collaboration, clinical trials, AI/ML, digital health - Read more

Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M
Acquisition, sleep disorders, small molecule, milestone payments - Read more

Gilead, Manta Cares partner to distribute lung and breast cancer patient navigation tools nationwide
Patient support collaboration, oncology, digital health, antibody-drug conjugate - Read more

Alnylam, Viz.ai partner on cardiac amyloidosis care pathway for earlier diagnosis, financial terms undisclosed
Research collaboration, AI/ML, diagnostics, rare disease - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Ocugen advances OCU410 gene therapy targeting RORA to Ph3 for geographic atrophy following positive Ph2 results
Gene therapy, ophthalmology, AAV vector, geographic atrophy, age-related macular degeneration, RORA target - Read more

Karyopharm Therapeutics' Xpovio meets primary endpoint in Ph3 myelofibrosis trial, mixed secondary results
Small molecule, blood disorders, XPO1 inhibitor, myelofibrosis, combination therapy, spleen volume reduction - Read more

Clockwork Bio launches as AI-native drug discovery platform targeting oncology with autonomous cell state control
AI-based drug discovery, oncology, strategic, operational - Read more

Immutrin raises $87M Series A, antibody therapy for progressive heart disease
Cardiovascular, antibody, rare disease, clinical-stage - Read more

Karyopharm Therapeutics raises $30M private placement for cancer therapy clinical trials
Oncology, small molecule, clinical-stage, commercial-stage - Read more

Gilgamesh Pharma raises $60M Series A, developing neuropsychiatric therapies for psychiatric disorders
Neuropsychiatric, small molecule, clinical-stage, NMDA receptor - Read more

RyboDyn raises $10M Seed funding, AI-powered platform for cancer immunotherapy discovery
Cancer, AI/ML platform, antibody, platform technology, biomarker discovery - Read more

EpiFrontier Therapeutics raises $32M grant funding for beta globin disorder therapies
Rare disease, small molecule, clinical-stage, G9a inhibition - Read more

UCB to build $2B biologics manufacturing facility near Atlanta headquarters, creating 330 jobs
Biologics, strategic, major transaction, operational - Read more

Wilmington PharmaTech commits $50M to double Delaware API manufacturing capacity by Q3 2027
Small molecule, strategic, major transaction, operational, manufacturing expansion - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Aardvark pauses 2 obesity trials, reveals new details on cardiac concerns
Small molecule, metabolic, obesity, GLP-1 receptor, cardiac safety, combination therapy - Read more

FDA issues warning letter to ImmunityBio over false, misleading Anktiva cancer drug promotional claims
Immunotherapy, oncology, regulatory, operational - Read more

Eli Lilly to discontinue multiple insulin products across European markets by 2027 for commercial reasons
Insulin, diabetes, strategic, operational - Read more

SCOTUS allows RICO class action against Takeda and Eli Lilly over Actos diabetes drug to proceed
Small molecule, diabetes, financial, major transaction, competitive - Read more

Strides Pharma recalls 90K children's ibuprofen bottles after contamination complaints include gel-like mass, black particles
Small molecule, regulatory, operational, quality control - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here